Genvoya + Epclusa + Biktarvy
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HIV-1-infection
Conditions
HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence, Opioid Dependence, Bone Diseases, Metabolic, HIV/AIDS, Co-infection, Buprenorphine Dependence, HCV Coinfection
Trial Timeline
Feb 1, 2018 → Jun 22, 2021
NCT ID
NCT03549312About Genvoya + Epclusa + Biktarvy
Genvoya + Epclusa + Biktarvy is a approved stage product being developed by Gilead Sciences for HIV-1-infection. The current trial status is unknown. This product is registered under clinical trial identifier NCT03549312. Target conditions include HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence.
What happened to similar drugs?
11 of 18 similar drugs in HIV-1-infection were approved
Approved (11) Terminated (3) Active (6)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03549312 | Approved | UNKNOWN |
Competing Products
20 competing products in HIV-1-infection